Cabaletta Bio, Inc. (NASDAQ:CABA – Get Rating) insider Gwendolyn Binder sold 22,000 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $11.81, for a total value of $259,820.00. Following the completion of the transaction, the insider now owns 20,000 shares in the company, valued at approximately $236,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Cabaletta Bio Price Performance
NASDAQ CABA opened at $11.64 on Friday. The business’s fifty day moving average price is $9.28 and its 200-day moving average price is $8.19. The stock has a market capitalization of $364.98 million, a price-to-earnings ratio of -6.43 and a beta of 2.54. Cabaletta Bio, Inc. has a 1-year low of $0.59 and a 1-year high of $13.44.
Cabaletta Bio (NASDAQ:CABA – Get Rating) last released its quarterly earnings results on Thursday, March 16th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.05). Equities research analysts anticipate that Cabaletta Bio, Inc. will post -1.87 EPS for the current year.
Analysts Set New Price Targets
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marquette Asset Management LLC bought a new position in shares of Cabaletta Bio during the 4th quarter valued at approximately $125,000. Dimensional Fund Advisors LP bought a new position in shares of Cabaletta Bio during the 4th quarter valued at approximately $1,161,000. Jane Street Group LLC boosted its position in shares of Cabaletta Bio by 648.1% during the 3rd quarter. Jane Street Group LLC now owns 83,477 shares of the company’s stock valued at $54,000 after acquiring an additional 72,319 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Cabaletta Bio by 21.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,278,551 shares of the company’s stock valued at $831,000 after acquiring an additional 226,713 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Cabaletta Bio by 105.2% during the 3rd quarter. Renaissance Technologies LLC now owns 687,461 shares of the company’s stock valued at $447,000 after acquiring an additional 352,461 shares during the last quarter. 62.12% of the stock is currently owned by institutional investors.
About Cabaletta Bio
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
- Get a free copy of the StockNews.com research report on Cabaletta Bio (CABA)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.